Spyre Therapeutics, Inc. (SYRE) Insider Trading Disclosures
Spyre Therapeutics, Inc. (SYRE) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: SYRE
CIK: 1636282
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
KPMG LLP
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerEdward Bryant
Audit LocationSan Diego, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13D/A | 2026-10-09 | — | SCHEDULE 13D/A Filing | 0001104659-26-115087 | View SEC Doc Filr Page |
| 8-K | 2026-10-07 | 2026-10-05 | 8-K | 0001628280-26-065291 | View SEC Doc Filr Page |
| 424B5 | 2026-10-06 | — | 424B5 | 0001628280-26-065249 | View SEC Doc Filr Page |
| 424B5 | 2026-10-05 | — | 424B5 | 0001628280-26-064924 | View SEC Doc Filr Page |
| 4 | 2026-10-02 | 2026-10-01 | FORM 4 | 0001636282-26-000119 | View SEC Doc Filr Page |
| 4 | 2026-10-02 | 2026-10-01 | FORM 4 | 0001636282-26-000118 | View SEC Doc Filr Page |
| 4 | 2026-10-02 | 2026-09-30 | FORM 4 | 0001636282-26-000117 | View SEC Doc Filr Page |
| 144 | 2026-10-01 | — | 144 Filing | 0001950047-26-009978 | View SEC Doc Filr Page |
| 144 | 2026-10-01 | — | 144 Filing | 0001950047-26-009971 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-10-01 | — | SCHEDULE 13G Filing | 0001104659-26-112828 | View SEC Doc Filr Page |
| 144 | 2026-09-30 | — | 144 Filing | 0001950047-26-009876 | View SEC Doc Filr Page |
| 8-K | 2026-09-08 | 2026-09-08 | 8-K | 0001636282-26-000113 | View SEC Doc Filr Page |
| 4 | 2026-09-03 | 2026-09-01 | FORM 4 | 0001636282-26-000111 | View SEC Doc Filr Page |
| 4 | 2026-09-03 | 2026-09-01 | FORM 4 | 0001636282-26-000109 | View SEC Doc Filr Page |
| 4 | 2026-09-03 | 2026-09-01 | FORM 4 | 0001636282-26-000107 | View SEC Doc Filr Page |
| 144 | 2026-09-01 | — | 144 Filing | 0001950047-26-008970 | View SEC Doc Filr Page |
| 8-K | 2026-08-25 | 2026-08-25 | 8-K | 0001636282-26-000105 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001193125-26-352655 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001493215-26-000157 | View SEC Doc Filr Page |
| 4 | 2026-08-10 | 2026-08-07 | FORM 4 | 0001636282-26-000102 | View SEC Doc Filr Page |
| 144 | 2026-08-07 | — | 144 Filing | 0001950047-26-007821 | View SEC Doc Filr Page |
| 144 | 2026-08-07 | — | 144 Filing | 0001950047-26-007819 | View SEC Doc Filr Page |
| 4 | 2026-08-05 | 2026-08-03 | FORM 4 | 0001636282-26-000100 | View SEC Doc Filr Page |
| 4 | 2026-08-05 | 2026-08-03 | FORM 4 | 0001636282-26-000099 | View SEC Doc Filr Page |
| 8-K | 2026-08-04 | 2026-08-04 | 8-K | 0001636282-26-000098 | View SEC Doc Filr Page |